deferoxamine has been researched along with Atrophy in 10 studies
Deferoxamine: Natural product isolated from Streptomyces pilosus. It forms iron complexes and is used as a chelating agent, particularly in the mesylate form.
desferrioxamine B : An acyclic desferrioxamine that is butanedioic acid in which one of the carboxy groups undergoes formal condensation with the primary amino group of N-(5-aminopentyl)-N-hydroxyacetamide and the second carboxy group undergoes formal condensation with the hydroxyamino group of N(1)-(5-aminopentyl)-N(1)-hydroxy-N(4)-[5-(hydroxyamino)pentyl]butanediamide. It is a siderophore native to Streptomyces pilosus biosynthesised by the DesABCD enzyme cluster as a high affinity Fe(III) chelator.
Atrophy: Decrease in the size of a cell, tissue, organ, or multiple organs, associated with a variety of pathological conditions such as abnormal cellular changes, ischemia, malnutrition, or hormonal changes.
Excerpt | Relevance | Reference |
---|---|---|
"Deferoxamine (DFX), a potent iron-chelating agent, reduces brain edema and neuronal cell injury that develop due to the hemolysis cascade." | 7.78 | Effects of statin and deferoxamine administration on neurological outcomes in a rat model of intracerebral hemorrhage. ( Chun, HJ; Hwang, SJ; Jwa, CS; Kim, DW; Kim, EH; Kim, YS; Lee, YK; Ryou, H; Yi, HJ, 2012) |
"Deferoxamine (DFX) reduces brain edema, neurological deficits, and brain atrophy after intracerebral hemorrhage (ICH) in aged and young rats." | 7.76 | Deferoxamine treatment for intracerebral hemorrhage in aged rats: therapeutic time window and optimal duration. ( Hua, Y; Keep, RF; Morgenstern, LB; Okauchi, M; Schallert, T; Xi, G, 2010) |
"Deferoxamine (DFX) reduces brain edema, neuronal death, and neurological deficits after intracerebral hemorrhage (ICH) in young rats." | 7.75 | Effects of deferoxamine on intracerebral hemorrhage-induced brain injury in aged rats. ( Hua, Y; Keep, RF; Morgenstern, LB; Okauchi, M; Xi, G, 2009) |
"Deferoxamine (DFX), a potent iron-chelating agent, reduces brain edema and neuronal cell injury that develop due to the hemolysis cascade." | 3.78 | Effects of statin and deferoxamine administration on neurological outcomes in a rat model of intracerebral hemorrhage. ( Chun, HJ; Hwang, SJ; Jwa, CS; Kim, DW; Kim, EH; Kim, YS; Lee, YK; Ryou, H; Yi, HJ, 2012) |
"Deferoxamine (DFX) reduces brain edema, neurological deficits, and brain atrophy after intracerebral hemorrhage (ICH) in aged and young rats." | 3.76 | Deferoxamine treatment for intracerebral hemorrhage in aged rats: therapeutic time window and optimal duration. ( Hua, Y; Keep, RF; Morgenstern, LB; Okauchi, M; Schallert, T; Xi, G, 2010) |
"Deferoxamine (DFX) reduces brain edema, neuronal death, and neurological deficits after intracerebral hemorrhage (ICH) in young rats." | 3.75 | Effects of deferoxamine on intracerebral hemorrhage-induced brain injury in aged rats. ( Hua, Y; Keep, RF; Morgenstern, LB; Okauchi, M; Xi, G, 2009) |
"Deferoxamine was used as an iron chelator." | 1.33 | Long-term effects of experimental intracerebral hemorrhage: the role of iron. ( Hoff, JT; Hua, Y; Keep, RF; Nakamura, T; Schallert, T; Wu, J; Xi, G, 2006) |
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 4 (40.00) | 29.6817 |
2010's | 5 (50.00) | 24.3611 |
2020's | 1 (10.00) | 2.80 |
Authors | Studies |
---|---|
Vinke, JSJ | 1 |
Gorter, AR | 1 |
Eisenga, MF | 1 |
Dam, WA | 1 |
van der Meer, P | 1 |
van den Born, J | 1 |
Bakker, SJL | 1 |
Hoes, MF | 1 |
de Borst, MH | 1 |
Jauregui, R | 1 |
Park, KS | 1 |
Bassuk, AG | 1 |
Mahajan, VB | 1 |
Tsang, SH | 1 |
Qin, Y | 1 |
Li, G | 1 |
Sun, Z | 1 |
Xu, X | 1 |
Gu, J | 1 |
Gao, F | 1 |
Okauchi, M | 2 |
Hua, Y | 3 |
Keep, RF | 3 |
Morgenstern, LB | 2 |
Xi, G | 3 |
Schallert, T | 2 |
Chun, HJ | 1 |
Kim, DW | 1 |
Yi, HJ | 1 |
Kim, YS | 1 |
Kim, EH | 1 |
Hwang, SJ | 1 |
Jwa, CS | 1 |
Lee, YK | 1 |
Ryou, H | 1 |
Zhang, L | 1 |
Hu, R | 1 |
Li, M | 1 |
Li, F | 1 |
Meng, H | 1 |
Zhu, G | 1 |
Lin, J | 1 |
Feng, H | 1 |
Arora, A | 1 |
Wren, S | 1 |
Gregory Evans, K | 1 |
Morad, Y | 1 |
Banin, E | 1 |
Averbukh, E | 1 |
Berenshtein, E | 1 |
Obolensky, A | 1 |
Chevion, M | 1 |
Nakamura, T | 1 |
Wu, J | 1 |
Hoff, JT | 1 |
Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
---|---|---|---|---|---|---|---|
Safety and Effectiveness Study of Deferoxamine and Xingnaojing Injection in Intracerebral Hemorrhage[NCT02367248] | Phase 1/Phase 2 | 180 participants (Anticipated) | Interventional | 2015-03-31 | Recruiting | ||
Futility Study of Deferoxamine in Intracerebral Hemorrhage[NCT01662895] | Phase 2 | 42 participants (Actual) | Interventional | 2013-03-18 | Terminated (stopped due to By DSMB on October 18, 2013 due to increased incidence of ARDS. See modified protocol [NCT02175225) | ||
Study of Deferoxamine Mesylate in Intracerebral Hemorrhage[NCT02175225] | Phase 2 | 294 participants (Actual) | Interventional | 2014-10-31 | Completed | ||
[information is prepared from clinicaltrials.gov, extracted Sep-2024] |
Mortality at any time from randomization through day-90 (NCT01662895)
Timeframe: 90 days
Intervention | Participants (Count of Participants) |
---|---|
Deferoxamine | 3 |
Normal Saline | 0 |
(NCT01662895)
Timeframe: within 7 days or discharge
Intervention | Participants (Count of Participants) |
---|---|
Deferoxamine | 1 |
Normal Saline | 1 |
(NCT01662895)
Timeframe: within 7 days or discharge
Intervention | Participants (Count of Participants) |
---|---|
Deferoxamine | 0 |
Normal Saline | 1 |
(NCT01662895)
Timeframe: 90 days
Intervention | Participants (Count of Participants) |
---|---|
Deferoxamine | 9 |
Normal Saline | 6 |
(NCT01662895)
Timeframe: 90 days
Intervention | Participants (Count of Participants) |
---|---|
Deferoxamine | 6 |
Normal Saline | 0 |
(NCT01662895)
Timeframe: within 7 days or discharge
Intervention | Participants (Count of Participants) |
---|---|
Deferoxamine | 0 |
Normal Saline | 0 |
"The primary outcome measure of efficacy is the modified Rankin Scale (mRS) score, dichotomized to define good functional outcome as mRS 0-2 at 90 days.~The minimum mRS score is 0 (i.e. no disability). The maximum score is 6 (i.e. dead)." (NCT01662895)
Timeframe: 90 days
Intervention | Participants (Count of Participants) |
---|---|
Deferoxamine | 6 |
Normal Saline | 10 |
The proportion of DFO- and placebo-treated subjects with mRS 0-3 vs. 4-6 at 90 days (NCT01662895)
Timeframe: 90 days
Intervention | Participants (Count of Participants) |
---|---|
Deferoxamine | 12 |
Normal Saline | 14 |
Adverse event of special interest: anaphylaxis at any time during the study infusion (NCT02175225)
Timeframe: during the study infusion
Intervention | Participants (Count of Participants) |
---|---|
Deferoxamine Mesylate | 3 |
Normal Saline | 0 |
Hypotension requiring medical intervention at any time during the study infusion that could not be explained by other causes (NCT02175225)
Timeframe: during the study infusion
Intervention | Participants (Count of Participants) |
---|---|
Deferoxamine Mesylate | 1 |
Normal Saline | 2 |
Adverse event of special interest: development of new and unexplained visual or auditory changes after initiation of the study infusion (NCT02175225)
Timeframe: after initiation of study infusion
Intervention | Participants (Count of Participants) |
---|---|
Deferoxamine Mesylate | 3 |
Normal Saline | 4 |
Edema accompanied by an unexplained increase of more than four points on the US National Institutes of Health Stroke Scale or a decrease of more than two points in Glasgow Coma Scale score during the first week after the intracerebral haemorrhage. (NCT02175225)
Timeframe: 7 days
Intervention | Participants (Count of Participants) |
---|---|
Deferoxamine Mesylate | 9 |
Normal Saline | 5 |
Number of subjects experiencing Serious adverse events at any time from randomization through day 90 (NCT02175225)
Timeframe: 90 days
Intervention | Participants (Count of Participants) |
---|---|
Deferoxamine Mesylate | 39 |
Normal Saline | 49 |
Number of Subjects Experiencing Serious Adverse Events within 7 days of randomization (NCT02175225)
Timeframe: 7 days
Intervention | Participants (Count of Participants) |
---|---|
Deferoxamine Mesylate | 24 |
Normal Saline | 26 |
Another measure of efficacy is the modified Rankin Scale (mRS) score, dichotomized to define good functional outcome as mRS 0-2 at 180 days. The mRS ranges from 0 to 6, with higher scores indicating worse outcome. (NCT02175225)
Timeframe: 180 days
Intervention | Participants (Count of Participants) |
---|---|
Deferoxamine Mesylate | 61 |
Normal Saline | 48 |
The primary outcome measure of efficacy is the modified Rankin Scale (mRS) score, dichotomized to define good functional outcome as mRS 0-2 at 90 days. The mRS ranges from 0 to 6, with higher scores indicating worse outcome. (NCT02175225)
Timeframe: 90 days
Intervention | Participants (Count of Participants) |
---|---|
Deferoxamine Mesylate | 48 |
Normal Saline | 47 |
Another measure of efficacy is the modified Rankin Scale (mRS) score, dichotomized to define good functional outcome as mRS 0-3 at 180 days. The mRS ranges from 0 to 6, with higher scores indicating worse outcome. (NCT02175225)
Timeframe: 180 days
Intervention | Participants (Count of Participants) |
---|---|
Deferoxamine Mesylate | 97 |
Normal Saline | 92 |
"Another measure of efficacy is the modified Rankin Scale (mRS) score, dichotomized to define good functional outcome as mRS 0-3 at 90 days. The mRS ranges from 0 to 6, with higher scores indicating worse outcome.~Although mRS 0-3 is less favorable than the primary outcome of mRS 0-2, it would still be a desirable effect in patients with ICH given that no treatments exist to reduce disability." (NCT02175225)
Timeframe: 90 days
Intervention | Participants (Count of Participants) |
---|---|
Deferoxamine Mesylate | 91 |
Normal Saline | 82 |
Adverse event of special interest: Respiratory compromise of any cause, including acute respiratory distress syndrome, in hospital until day 7 or discharge [whichever was earlier] (NCT02175225)
Timeframe: 7 days
Intervention | Participants (Count of Participants) | |
---|---|---|
All cause | Cause by acute respiratory distress syndrome | |
Deferoxamine Mesylate | 20 | 2 |
Normal Saline | 23 | 1 |
Analyses will be expanded to include an interaction between treatment and OTT window and the magnitude of the treatment effect, and corresponding confidence interval, will be estimated for each time window (<12 hours vs. >/= 12 hours) in order to explore the presence of a differential treatment effect in the OTT windows. (NCT02175225)
Timeframe: 90 days
Intervention | Participants (Count of Participants) | |
---|---|---|
Onset to treatment time <=12 hours | Onset to treatment time >12 hours | |
Deferoxamine Mesylate | 15 | 33 |
Normal Saline | 19 | 28 |
10 other studies available for deferoxamine and Atrophy
Article | Year |
---|---|
Iron deficiency is related to lower muscle mass in community-dwelling individuals and impairs myoblast proliferation.
Topics: Adult; Animals; Atrophy; Cell Proliferation; Deferoxamine; Female; Ferritins; Humans; Independent Li | 2023 |
Deferoxamine-induced electronegative ERG responses.
Topics: Atrophy; Deferoxamine; Electroretinography; Fluorescein Angiography; Humans; Iron Overload; Male; Mi | 2018 |
Comparison of the effects of nimodipine and deferoxamine on brain injury in rat with subarachnoid hemorrhage.
Topics: Animals; Atrophy; Cognitive Dysfunction; Deferoxamine; Disease Models, Animal; Ferritins; Male; Maze | 2019 |
Effects of deferoxamine on intracerebral hemorrhage-induced brain injury in aged rats.
Topics: Animals; Atrophy; Behavior, Animal; Blood Pressure; Body Water; Body Weight; Brain; Brain Diseases; | 2009 |
Effects of deferoxamine on intracerebral hemorrhage-induced brain injury in aged rats.
Topics: Animals; Atrophy; Behavior, Animal; Blood Pressure; Body Water; Body Weight; Brain; Brain Diseases; | 2009 |
Effects of deferoxamine on intracerebral hemorrhage-induced brain injury in aged rats.
Topics: Animals; Atrophy; Behavior, Animal; Blood Pressure; Body Water; Body Weight; Brain; Brain Diseases; | 2009 |
Effects of deferoxamine on intracerebral hemorrhage-induced brain injury in aged rats.
Topics: Animals; Atrophy; Behavior, Animal; Blood Pressure; Body Water; Body Weight; Brain; Brain Diseases; | 2009 |
Deferoxamine treatment for intracerebral hemorrhage in aged rats: therapeutic time window and optimal duration.
Topics: Aging; Animals; Atrophy; Brain Edema; Caudate Nucleus; Cerebral Hemorrhage; Deferoxamine; Disease Mo | 2010 |
Deferoxamine treatment for intracerebral hemorrhage in aged rats: therapeutic time window and optimal duration.
Topics: Aging; Animals; Atrophy; Brain Edema; Caudate Nucleus; Cerebral Hemorrhage; Deferoxamine; Disease Mo | 2010 |
Deferoxamine treatment for intracerebral hemorrhage in aged rats: therapeutic time window and optimal duration.
Topics: Aging; Animals; Atrophy; Brain Edema; Caudate Nucleus; Cerebral Hemorrhage; Deferoxamine; Disease Mo | 2010 |
Deferoxamine treatment for intracerebral hemorrhage in aged rats: therapeutic time window and optimal duration.
Topics: Aging; Animals; Atrophy; Brain Edema; Caudate Nucleus; Cerebral Hemorrhage; Deferoxamine; Disease Mo | 2010 |
Effects of statin and deferoxamine administration on neurological outcomes in a rat model of intracerebral hemorrhage.
Topics: Analysis of Variance; Animals; Atrophy; Brain Edema; CD11b Antigen; Cerebral Hemorrhage; Deferoxamin | 2012 |
Deferoxamine attenuates iron-induced long-term neurotoxicity in rats with traumatic brain injury.
Topics: Analysis of Variance; Animals; Apoferritins; Atrophy; Brain; Brain Injuries; Deferoxamine; Disease M | 2013 |
Desferrioxamine related maculopathy: a case report.
Topics: Aged; Aged, 80 and over; Atrophy; Deferoxamine; Diagnosis, Differential; Female; Glaucoma, Open-Angl | 2004 |
Treatment of ocular tissues exposed to nitrogen mustard: beneficial effect of zinc desferrioxamine combined with steroids.
Topics: Animals; Atrophy; Burns, Chemical; Chemical Warfare Agents; Corneal Diseases; Corneal Neovasculariza | 2005 |
Long-term effects of experimental intracerebral hemorrhage: the role of iron.
Topics: Animals; Atrophy; Behavior, Animal; Brain; Deferoxamine; Ferritins; Intracranial Hemorrhages; Iron; | 2006 |